Edwards Lifesciences - EW Stock Forecast, Price & News

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $100.53 on Thursday. The business's 50-day moving average price is $98.15 and its 200 day moving average price is $104.98. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10. The firm has a market cap of $62.32 billion, a P/E ratio of 43.52, a P/E/G ratio of 3.01 and a beta of 1.12. Edwards Lifesciences has a 52-week low of $85.58 and a 52-week high of $131.73.

Edwards Lifesciences (NYSE:EW - Get Rating) last released its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the firm posted $0.64 EPS. The company's revenue for the quarter was down .2% on a year-over-year basis. On average, equities research analysts expect that Edwards Lifesciences will post 2.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Morgan Stanley decreased their target price on Edwards Lifesciences from $136.00 to $119.00 and set an "overweight" rating on the stock in a research note on Friday, July 15th. Canaccord Genuity Group cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and reduced their price target for the stock from $115.00 to $106.00 in a research report on Friday, July 29th. Citigroup dropped their price objective on shares of Edwards Lifesciences from $134.00 to $115.00 and set a "buy" rating for the company in a report on Tuesday, May 17th. Cowen cut their price objective on Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Finally, William Blair reissued an "outperform" rating on shares of Edwards Lifesciences in a research note on Tuesday, April 26th. Three investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $126.19.

Insider Activity

In other Edwards Lifesciences news, VP Bernard J. Zovighian sold 4,809 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The stock was sold at an average price of $95.52, for a total transaction of $459,355.68. Following the transaction, the vice president now owns 39,816 shares in the company, valued at approximately $3,803,224.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,000 shares of the company's stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $98.31, for a total transaction of $98,310.00. Following the transaction, the vice president now directly owns 19,911 shares in the company, valued at $1,957,450.41. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Bernard J. Zovighian sold 4,809 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $95.52, for a total transaction of $459,355.68. Following the sale, the vice president now owns 39,816 shares of the company's stock, valued at $3,803,224.32. The disclosure for this sale can be found here. Insiders have sold a total of 100,937 shares of company stock valued at $9,738,239 over the last quarter. Corporate insiders own 1.29% of the company's stock.